Pictet Asset Management (UK)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pictet Asset Management (UK)’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$34.2M	Buy	211,603 +78,547	+59%	+$12.6M	0.04%	418
2021 Q1	$22.8M	Sell	133,056 -1,332	-1%	-$264K	0.03%	478
2020 Q4	$29.5M	Buy	134,388 +53,465	+66%	+$11.6M	0.04%	407
2020 Q3	$13.4M	Sell	80,923 -212	-0.3%	-$29K	0.02%	496
2020 Q2	$9.26M	Buy	81,135 +22,862	+39%	+$2.22M	0.02%	541
2020 Q1	$4.48M	Sell	58,273 -56,066	-49%	-$5.03M	0.01%	675
2019 Q4	$14.7M	Sell	114,339 -153,095	-57%	-$14.8M	0.03%	503
2019 Q3	$20.8M	Buy	267,434 +117,726	+79%	+$11M	0.04%	381
2019 Q2	$15.4M	Sell	149,708 -86,267	-37%	-$6.72M	0.03%	443
2019 Q1	$17.3M	Buy	235,975 +2,141	+0.9%	+$146K	0.04%	433
2018 Q4	$9.92K	Buy	233,834 +42,305	+22%	+$1.69M	0.02%	509
2018 Q3	$9.02M	Buy	+191,529	New	+$10.7M	0.02%	590

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pictet Asset Management (UK)'s MRTX Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 59% in Q2 2021, buying an estimated $12.6M and bringing the position to 211,603 shares worth $34.2M. The position accounts for 0.04% of the portfolio, ranked #418.

Pictet Asset Management (UK) first reported a position in MRTX in Q3 2018 and has held it in 12 quarters since. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

Pictet Asset Management (UK) held 211,603 shares of Mirati Therapeutics, Inc. Common Stock worth $34.2M as of Q2 2021.
Pictet Asset Management (UK) bought 78,547 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $12.6M.
Mirati Therapeutics, Inc. Common Stock made up 0.04% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #418 holding.
Pictet Asset Management (UK) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and has held it in 12 quarters since.
245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.